The global market for benign breast disease and early breast cancer diagnostics is experiencing significant growth due to rising incidences of these conditions worldwide. A key driver of this phenomenon is the maturing population, coupled with enhanced diagnostic capabilities and technologies. The market is segmented into various categories based o